Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;31(5):1217-1220.
doi: 10.1038/leu.2017.22. Epub 2017 Jan 18.

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

R F Schlenk  1   2 , P Frech  1 , D Weber  1 , P Brossart  3 , H-A Horst  4 , D Kraemer  5 , G Held  6 , M Ringhoffer  7 , A Burchardt  8 , G Kobbe  9 , K Götze  10 , D Nachbaur  11 , T Fischer  12 , M Lübbert  13 , H R Salih  14 , H Salwender  15 , G Wulf  16 , E Koller  17 , M Wattad  18 , W Fiedler  19 , S Kremers  20 , H Kirchen  21 , B Hertenstein  22 , P Paschka  1 , V I Gaidzik  1 , V Teleanu  1 , M Heuser  23 , F Thol  23 , K Döhner  1 , J Krauter  23 , A Ganser  23 , H Döhner  1 ; the German-Austrian AMLSG
Affiliations

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

R F Schlenk et al. Leukemia. 2017 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan−Meier plot illustrating the influence of the CR/CRi probability score on survival after relapse in patients receiving intensive salvage chemotherapy (a) or direct allogeneic HCT (b) as treatment of relapse. The score was based on the sum of favorable (+1) and unfavorable (−1) parameters defining three groups: low CR/CRi probability value<0; intermediate CR/CRi probability value=0, high CR/CRi probability value>0.
See this image and copyright information in PMC

References

    1. Schlenk RF, Döhner H. Genomic applications in the clinic: use in treatment paradigm of AML. Am Soc Hematol Educ Program 2013; 2013: 324–330. - PubMed
    1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015; 373: 1136–1152. - PubMed
    1. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474. - PubMed
    1. Ravandi F. Relapsed acute myeloid leukemia: why is there no standard of care? Best Pract Res Clin Haematol 2013; 26: 253–259. - PMC - PubMed
    1. Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23: 1969–1978. - PubMed